Nuvectis corrects title of ciprocopan China marketing approval release
NVCT•Correction to prior release title
- Nuvectis issued a correction to its release, changing only the title.
- The corrected title states ciprocopan (NXP100) won China marketing clearance for PNH patients not previously treated with complement inhibitors.
